Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Upgraded by Kepler Capital Markets to "Buy" Rating

Kepler Capital Markets upgraded shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Free Report) from a hold rating to a buy rating in a research note released on Wednesday, MarketBeat.com reports.

Other analysts have also issued reports about the company. Wall Street Zen upgraded Bayer Aktiengesellschaft from a "hold" rating to a "buy" rating in a report on Friday, June 6th. The Goldman Sachs Group raised Bayer Aktiengesellschaft from a "hold" rating to a "strong-buy" rating in a research report on Thursday, June 5th. Finally, Hsbc Global Res raised Bayer Aktiengesellschaft to a "hold" rating in a research report on Monday, April 28th. Two analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, Bayer Aktiengesellschaft currently has a consensus rating of "Moderate Buy".

Bayer Aktiengesellschaft Stock Up 4.3%

OTCMKTS BAYRY traded up $0.33 during trading hours on Wednesday, reaching $7.95. 640,858 shares of the company's stock were exchanged, compared to its average volume of 814,784. The company has a debt-to-equity ratio of 1.19, a quick ratio of 0.81 and a current ratio of 1.32. The company has a market capitalization of $31.24 billion, a price-to-earnings ratio of -30.58 and a beta of 0.85. The company's 50-day moving average is $6.57 and its two-hundred day moving average is $5.92. Bayer Aktiengesellschaft has a one year low of $4.79 and a one year high of $8.58.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The company reported $0.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.63 by $0.02. The company had revenue of $15.27 billion during the quarter, compared to the consensus estimate of $13.39 billion. Bayer Aktiengesellschaft had a negative net margin of 2.02% and a positive return on equity of 16.90%. On average, analysts forecast that Bayer Aktiengesellschaft will post 1.31 EPS for the current fiscal year.

Bayer Aktiengesellschaft Increases Dividend

The business also recently disclosed a dividend, which was paid on Monday, May 12th. Stockholders of record on Wednesday, April 30th were issued a $0.0224 dividend. This is a boost from Bayer Aktiengesellschaft's previous dividend of $0.02. The ex-dividend date of this dividend was Tuesday, April 29th. This represents a dividend yield of 0.38%. Bayer Aktiengesellschaft's dividend payout ratio (DPR) is presently -2.17%.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.